BR112022011226A2 - Anticorpos antiglicoproteína ib alfa (gpibalpha) humanizados - Google Patents

Anticorpos antiglicoproteína ib alfa (gpibalpha) humanizados

Info

Publication number
BR112022011226A2
BR112022011226A2 BR112022011226A BR112022011226A BR112022011226A2 BR 112022011226 A2 BR112022011226 A2 BR 112022011226A2 BR 112022011226 A BR112022011226 A BR 112022011226A BR 112022011226 A BR112022011226 A BR 112022011226A BR 112022011226 A2 BR112022011226 A2 BR 112022011226A2
Authority
BR
Brazil
Prior art keywords
antibodies
alpha
glycoprotein
platelet
gpibalpha
Prior art date
Application number
BR112022011226A
Other languages
English (en)
Inventor
Ni Heyu
Original Assignee
Ccoa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ccoa Therapeutics Inc filed Critical Ccoa Therapeutics Inc
Publication of BR112022011226A2 publication Critical patent/BR112022011226A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ANTICORPOS ANTIGLICOPROTEÍNA IB ALFA (GPIBALPHA) HUMANIZADOS. Trata-se de anticorpos antiglicoproteína de plaqueta I(b)alfa multivalentes que podem provocar efeitos colaterais graves. A presente divulgação fornece anticorpos humanizados que reconhecem especificamente glicoproteína I(b)alfa e que carecem de uma porção de Fc, portanto, não interagem com receptor de Fc. Os anticorpos humanizados têm capacidade para evitar a ativação e agregação de plaqueta, e reduzir tamanho/crescimento de trombo e evitar oclusão de vaso. Os mesmos também podem ser muito úteis para diminuir interação entre plaqueta e célula tumoral e diminuir metástase tumoral. Em doses terapêuticas, os anticorpos humanizados carecem da habilidade em induzir ativação de plaqueta, induzir trombocitopenia; e/ou prolongar tempo de sangramento.
BR112022011226A 2019-12-10 2020-12-10 Anticorpos antiglicoproteína ib alfa (gpibalpha) humanizados BR112022011226A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962946086P 2019-12-10 2019-12-10
PCT/CA2020/051699 WO2021113974A1 (en) 2019-12-10 2020-12-10 Humanized anti-glycoprotein ib alpha (gpibalpha) antibodies

Publications (1)

Publication Number Publication Date
BR112022011226A2 true BR112022011226A2 (pt) 2022-08-30

Family

ID=74971870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011226A BR112022011226A2 (pt) 2019-12-10 2020-12-10 Anticorpos antiglicoproteína ib alfa (gpibalpha) humanizados

Country Status (17)

Country Link
US (1) US20230022143A1 (pt)
EP (1) EP4073123A4 (pt)
JP (1) JP2023506772A (pt)
KR (1) KR20220127250A (pt)
CN (1) CN112500483B (pt)
AU (1) AU2020399790A1 (pt)
BR (1) BR112022011226A2 (pt)
CA (1) CA3159975A1 (pt)
CL (1) CL2022001504A1 (pt)
CO (1) CO2022008680A2 (pt)
CU (1) CU20220035A7 (pt)
IL (1) IL293736A (pt)
MX (1) MX2022007118A (pt)
PE (1) PE20221325A1 (pt)
TW (1) TWI786485B (pt)
WO (1) WO2021113974A1 (pt)
ZA (1) ZA202207325B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113264995A (zh) * 2021-05-26 2021-08-17 苏州大学 一种血小板GPIbα蛋白相关的抗原表位肽及其应用
WO2023007182A1 (en) * 2021-07-29 2023-02-02 The University Of Birmingham Protein interaction inhibitors
CN113663822B (zh) * 2021-08-20 2023-12-05 中国人民解放军陆军军医大学第一附属医院 一种富血小板纤维蛋白凝胶的分离方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1051620B1 (en) * 1998-10-30 2006-06-07 Jonathan L. Miller Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
GB9918788D0 (en) * 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
US8323652B2 (en) * 2008-11-14 2012-12-04 Canadian Blood Services Antibodies against GPIbα
CN102988983B (zh) * 2011-09-09 2014-06-11 苏州苏大赛尔免疫生物技术有限公司 抗人血小板膜糖蛋白Ibα嵌合抗体药物组合物
CN107082809B (zh) * 2017-06-13 2020-11-10 华东理工大学 靶向血小板膜糖蛋白GPIbα的抑制肿瘤转移的单克隆抗体及其筛选方法

Also Published As

Publication number Publication date
ZA202207325B (en) 2022-08-31
CN112500483B (zh) 2022-11-29
EP4073123A1 (en) 2022-10-19
PE20221325A1 (es) 2022-09-09
WO2021113974A1 (en) 2021-06-17
MX2022007118A (es) 2022-10-03
IL293736A (en) 2022-08-01
TW202123972A (zh) 2021-07-01
TWI786485B (zh) 2022-12-11
CL2022001504A1 (es) 2023-02-03
JP2023506772A (ja) 2023-02-20
US20230022143A1 (en) 2023-01-26
CN112500483A (zh) 2021-03-16
AU2020399790A1 (en) 2022-07-14
CU20220035A7 (es) 2023-01-16
CO2022008680A2 (es) 2022-06-30
EP4073123A4 (en) 2024-01-10
CA3159975A1 (en) 2021-06-17
KR20220127250A (ko) 2022-09-19

Similar Documents

Publication Publication Date Title
BR112022011226A2 (pt) Anticorpos antiglicoproteína ib alfa (gpibalpha) humanizados
CL2020000299A1 (es) Compuestos, composiciones y métodos.
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
AR114541A1 (es) Constructos de anticuerpos para cldn18.2 y cd3
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
ECSP11011450A (es) ANTICUERPOS ANTI-TNF-a Y SUS USOS
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
CO2018009120A2 (es) Genes del factor viii optimizados
PE20160225A1 (es) Modulacion de la inmunidad tumoral
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20140357A (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20160950A1 (es) Biomarcadores de cancer y usos de los mismos
PE20200602A1 (es) Compuesto macrociclico y sus usos
PE20220258A1 (es) Terapia con linfocitos de infiltracion tumoral y sus usos
JOP20190103B1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
BR112022011339A2 (pt) Composições de células terapêuticas e métodos para fabricação e usos das mesmas
UY39436A (es) Proteínas de unión específicas y sus usos
BR112018077225A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas
BR112015021162A2 (pt) peptídeo tendo 5 epítopos de ctl ligados
BR112016030291A2 (pt) terapia de combinação